ebia Electrophoresis is 100% focused on the science of electrophoresis.
At least 10% of the annual budget is dedicated to research and development resulting in a
continuous stream of new and innovative electrophoresis product introductions. What’s new at Sebia?
New Innovation in Agarose Gel Electrophoresis Instrumentation:
The HYDRASYS® 2 instrument - new innovation for agarose gel electrophoresis testing.
The latest addition to our family of electrophoresis products,
the HYDRASYS 2 is a self-contained system which carries out all
the different phases of the electrophoresis testing including:
sample application, migration, incubation, staining, destaining, washing and drying.
The system includes a new, colored and back-lit touch screen for easy operations
along with optimized application with a new vertical application movement.
The HYDRASYS 2 is available in a traditional electrophoresis model, as
well as a FOCUSING model with IEF capabilities.
News from the FDA:
Sebia has received clearance from the Food and Drug Administration (FDA) to
market the MINICAP Hemoglobin assay – an aid in the diagnosis of hemoglobinopathies
and thalassemias. High-resolution separation and quantitation of normal and abnormal
hemoglobins takes place with capillary electrophoresis technology.
Sebia has received clearance from the FDA to market the
CAPILLARYS Urine kit,
which allows for the separation of urine proteins by capillary electrophoresis technology.
Sebia has received FDA clearance to market the
HYDRAGEL® A1AT Isofocusing
kit designed for the qualitative detection and identification of different phenotypes of A1AT.
This marks the first FDA cleared kit for A1AT Phenotyping. Phenotyping results, in conjunction with clinical findings and other
laboratory assays, aid in the diagnosis of A1AT deficiency –
the most common genetic cause of liver disease in children. A set of three FDA cleared A1AT Controls are also available.
Business Partnerships:
We would like to welcome each Beckman-Coulter electrophoresis customer to Sebia Electrophoresis.
To help support this transition process we have established a separate email address
(BC@Sebia-usa.com) for questions regarding the Beckman-Coulter and Sebia collaboration or
you could call us directly at 1-800-835-6497 and ask for the Sebia Transition Team for Paragon Products.
Welcome to the Sebia family and we look forward to working with you and your laboratory!
| 
